ABMD Stock Recent News

Yahoo Finance anchor Julie Hyman reports the latest headlines including a Judge blocking Penguin-Simon & Schuster deal, Delta pilots calling for strike, J&J planning to buy Abiomed and the Supreme Court blocking Congress from obtaining President Trumps tax returns.

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

ABIOMED Inc (NASDAQ: ABMD) opened about 50% up on Tuesday after Johnson & Johnson (NYSE: JNJ) said it will buy the heart pump maker for $16.6 billion.

Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

J&J's cardiovascular devices business will benefit from the $16.6 billion deal to acquire Abiomed. The deal comes at a time when J&J is spinning off its consumer health business.

Johnson & Johnson is set to buy medical device company Abiomed in cash for $380 per share. CNBC's 'Squawk Box' team breaks down the deal.

The pharmaceutical giant will buy the heart-pump maker for $380 a share.

Shares of Abiomed Inc. ABMD, -2.32% rocketed 48.8% toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acquired by Johnson & Johnson JNJ, -0.51% in a deal valued at $16.6 billion. Under terms of the deal, J&J will pay upfront $380 in cash for each Abiomed share outstanding, which represents a 50.7% premium to Monday's closing price of $252.08.

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.